Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC cut its holdings in Blueprint Medicines Co. (NASDAQ:BPMCGet Rating) by 0.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,313 shares of the biotechnology company’s stock after selling 302 shares during the quarter. Mutual of America Capital Management LLC owned approximately 0.07% of Blueprint Medicines worth $2,036,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of BPMC. Van ECK Associates Corp lifted its stake in shares of Blueprint Medicines by 16.0% during the first quarter. Van ECK Associates Corp now owns 1,548 shares of the biotechnology company’s stock valued at $99,000 after buying an additional 213 shares during the period. Nisa Investment Advisors LLC lifted its stake in shares of Blueprint Medicines by 50.7% during the second quarter. Nisa Investment Advisors LLC now owns 684 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 230 shares during the period. Principal Financial Group Inc. lifted its stake in shares of Blueprint Medicines by 2.0% during the first quarter. Principal Financial Group Inc. now owns 17,019 shares of the biotechnology company’s stock valued at $1,087,000 after buying an additional 339 shares during the period. Captrust Financial Advisors lifted its stake in shares of Blueprint Medicines by 2.5% during the first quarter. Captrust Financial Advisors now owns 16,206 shares of the biotechnology company’s stock valued at $1,035,000 after buying an additional 401 shares during the period. Finally, Steward Partners Investment Advisory LLC lifted its stake in shares of Blueprint Medicines by 414.2% during the first quarter. Steward Partners Investment Advisory LLC now owns 617 shares of the biotechnology company’s stock valued at $39,000 after buying an additional 497 shares during the period.

Blueprint Medicines Price Performance

BPMC opened at $44.83 on Thursday. The company has a fifty day simple moving average of $53.86 and a 200 day simple moving average of $57.60. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of -3.70 and a beta of 0.67. Blueprint Medicines Co. has a twelve month low of $40.78 and a twelve month high of $111.78. The company has a current ratio of 6.99, a quick ratio of 6.79 and a debt-to-equity ratio of 0.19.

Insider Activity at Blueprint Medicines

In other news, CEO Kate Haviland purchased 1,100 shares of the stock in a transaction that occurred on Thursday, November 3rd. The stock was acquired at an average cost of $43.98 per share, with a total value of $48,378.00. Following the acquisition, the chief executive officer now owns 92,281 shares in the company, valued at $4,058,518.38. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Blueprint Medicines news, insider Fouad Namouni sold 3,477 shares of the firm’s stock in a transaction on Tuesday, October 4th. The shares were sold at an average price of $67.30, for a total transaction of $234,002.10. Following the completion of the transaction, the insider now directly owns 52,797 shares of the company’s stock, valued at approximately $3,553,238.10. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Kate Haviland acquired 1,100 shares of the firm’s stock in a transaction on Thursday, November 3rd. The shares were bought at an average cost of $43.98 per share, with a total value of $48,378.00. Following the completion of the acquisition, the chief executive officer now owns 92,281 shares in the company, valued at $4,058,518.38. The disclosure for this purchase can be found here. Company insiders own 3.42% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on BPMC. SVB Leerink reduced their price objective on shares of Blueprint Medicines from $57.00 to $52.00 and set a “market perform” rating on the stock in a research note on Wednesday, November 2nd. Barclays cut their price target on shares of Blueprint Medicines from $70.00 to $58.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 2nd. The Goldman Sachs Group cut their price target on shares of Blueprint Medicines from $143.00 to $108.00 and set a “buy” rating on the stock in a research note on Thursday, November 3rd. StockNews.com began coverage on shares of Blueprint Medicines in a research note on Wednesday, October 12th. They set a “hold” rating on the stock. Finally, Jefferies Financial Group cut their price target on shares of Blueprint Medicines from $84.00 to $80.00 in a research note on Wednesday, November 2nd. Two analysts have rated the stock with a sell rating, six have issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $83.67.

Blueprint Medicines Company Profile

(Get Rating)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma.

Read More

Institutional Ownership by Quarter for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.